ResearchSafe

Pentosan (Joint Pain) (Pentosan Polysulfate Sodium (Cartrophen))

Category: Pain & Inflammation. Status: FDA Approved (interstitial cystitis) / Veterinary approved.

A semi-synthetic heparin-like polysaccharide with disease-modifying properties for osteoarthritis. Stimulates proteoglycan synthesis, inhibits cartilage-degrading enzymes, and improves synovial fluid quality for joint pain relief.

How it works

Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage. Stimulates hyaluronic acid production by synoviocytes. Promotes proteoglycan synthesis by chondrocytes. Reduces subchondral bone remodeling via anti-inflammatory effects.

Key facts

  • Molecular weight: ~4000-6000 Da (average)
  • Half-life: ~24 hours
  • Bioavailability: ~6% oral; ~100% subcutaneous
  • Storage: Room temperature. Sterile multi-use vial.

Dosing overview

  • Typical dose: 2-3 mg/kg SC (veterinary extrapolation) or 100mg oral 3x/day
  • Frequency: Weekly SC injections (4-6 course) or daily oral
  • Duration: 6-week SC course; 3-6 months oral
  • Route: Subcutaneous injection or oral capsule

Reported benefits

  • Cartilage protection and repair
  • Reduced joint inflammation
  • Improved synovial fluid
  • Disease-modifying (not just symptomatic)
  • Reduced bone marrow edema
  • Alternative to corticosteroid injections

Possible side effects

  • Mild bleeding risk (anti-coagulant properties)
  • Injection site bruising
  • GI upset (oral)
  • Rare: maculopathy (long-term high-dose oral)

Research

  • Pentosan polysulfate for knee osteoarthritis (2022): SC pentosan (2mg/kg weekly x6) reduced bone marrow lesions by 35% and pain scores by 45% on MRI at 6 months in knee OA.
  • Disease-modifying effects in OA (2021): Stimulated proteoglycan synthesis 2.5x and reduced MMP-13 activity by 60% in human cartilage explants.

Compare Pentosan (Joint Pain)

Research and educational reference only. Not medical advice.